Jefferies Initiates Coverage On Arcutis Biotherapeutics with Buy Rating, Announces Price Target of $15

2024-08-28 20:19

Jefferies analyst Kambiz Yazdi initiates coverage on Arcutis Biotherapeutics (NASDAQ: ARQT) with a Buy rating and announces Price Target of $15.

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。